BMS growth driver Camzyos fails in heart disease trial, denting expansion opportunity By Zoey Becker Apr 15, 2025 11:42am Bristol Myers Squibb Camzyos cardiomyopathy ...

Contineum Therapeutics has pumped the brakes on two projects, freeing up resources to go full speed ahead in its pursuit of Bristol Myers Squibb in idiopathic pulmonary fibrosis.

This BMS has all of these connections printed onto a PCB, but also included with the PCB is the high-power bus that would normally be taken care of by bus bar or nickel strips.

In a sign of how much the radiopharma race has heated up in recent months, BMS is paying $62.50 per share of the San Diego-based biotech, which equates to an equity value of $4.1 billion.